MindWalk Therapeutics (HYFT) - Koefisien utang jangka dawa marang modal

MindWalk Therapeutics - logo grafis emiten HYFT

The long-term debt-to-equity ratio demonstrates the debt sustainability of MindWalk Holdings (HYFT), where the value 0.41 describes the current level. MindWalk Holdings is scaling its AI services through partnerships with clinics, accelerating digital diagnostics. Neural networks are automating data collection, replacing a staff of analysts. However, the lack of stable revenue and dependence on investments create significant risks regarding engineer retention.

MindWalk Holdings, Inc. (HYFT): Utang jangka dawa marang ekuitas saka 05.09.2025 nganti 01.11.2026
Produk mawa merek MindWalk Holdings

MindWalk Holdings' adaptation to digital sovereignty requirements is reflected in its historical long-term debt-to-equity ratio. This metric determines the company's reliance on external borrowings with maturities exceeding one year. The ratio is calculated as long-term liabilities divided by shareholders' equity. An increase in this indicator signals liquidity risks, while a decrease suggests a potential investment deficit. This serves as a key indicator of the business's financial stability.

Analisis perusahaan pesaing

Haleon PLC - Kewajiban jangka dawa marang ekuitas|Utang jangka dawa marang modal KVUE|VRNA (Verona Pharma Inc.) - Koefisien utang jangka dawa marang modal|Utang jangka dawa marang modal MENS (Jyong Biotech Ltd)|Utang jangka dawa marang modal ligand.com LGND|AMRX - Utang jangka dawa marang ekuitas|Koefisien utang jangka dawa marang modal PRGO (Perrigo Company PLC)|Alvotech Corp (ALVO) - Utang jangka dawa marang ekuitas|Rasio utang jangka dawa marang ekuitas Liquidia Inc.|GLPG (Galapagos NV) - Utang jangka dawa marang modal|Utang jangka dawa marang modal anipharmaceuticals.com|Rasio utang jangka dawa marang ekuitas MNKD (MannKind)|AMPH (Amphastar Pharmaceuticals Inc) - Koefisien utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Pacira PCRX|ARS Corp (SPRY) - Kewajiban jangka dawa marang modal|TBPH: Rasio utang jangka dawa marang ekuitas|aquestive.com - Rasio silihan jangka dawa marang modal|SCPH: Utang jangka dawa marang modal|Tectonic Therapeutic - Koefisien utang jangka dawa marang modal|TNXP (Tonix Pharmaceuticals Inc.) - Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal SXT China SXTC|Utang jangka dawa marang ekuitas Eupraxia Pharmaceuticals (EPRX)|BHST (bioharvest.com) - Koefisien utang jangka dawa marang modal|Utang jangka dawa marang ekuitas eXoZymes EXOZ|ORMP - Rasio utang jangka dawa marang ekuitas|Entera Bio Corp - Utang jangka dawa marang modal|Rasio tanggungan utang jangka dawa marang modal ABVC BioPharma, Inc ABVC|Cumberland Pharmaceuticals (CPIX) - Utang jangka dawa marang ekuitas|Rasio utang jangka dawa marang modal QNTM|FGEN (FibroGen) - Utang jangka dawa marang modal|Rasio utang jangka dawa marang modal TELO (Telomir Pharmaceuticals Inc)|Rasio utang jangka dawa marang ekuitas RANI (Rani Therapeutics)|Rasio utang jangka dawa marang ekuitas synergychc.com SNYR|Utang jangka dawa marang modal RLYB (Rallybio)|Utang jangka dawa marang modal Lexaria Bioscience Corp LEXX|PULM - Utang jangka dawa marang ekuitas|PTHL: Utang jangka dawa marang ekuitas|aptorumgroup.com (APM) - Utang jangka dawa marang ekuitas|Lyra Therapeutics Inc (LYRA) - Utang jangka dawa marang modal|Rasio utang jangka dawa marang ekuitas IBO|TNFA: Koefisien utang jangka dawa marang modal|Utang jangka dawa marang modal YCBD|PRFX (PainReform Ltd) - Koefisien utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Altamira Therapeutics Ltd. CYTO|Lipella Pharma (LIPO) - Kewajiban jangka dawa marang modal|OPTN - Utang jangka dawa marang ekuitas|PIRS: Utang jangka dawa marang ekuitas|PROC: Utang jangka dawa marang modal|Rasio utang jangka dawa marang modal PTPI|QLI (Qilian International Holding Group Limited) - Utang jangka dawa marang modal|ACELYRIN Inc. (SLRN) - Rasio tanggungan utang jangka dawa marang modal|Utang jangka dawa marang ekuitas TFF Pharmaceuticals (TFFP)